Company / Free Cash Flow
Larimar Therapeutics, Inc. Free Cash Flow History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$43.8M
FY2019
5-year range
-$60.1M / -$15.0M
FY2015-FY2019
Trend
+16.7%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$60M to -$44M over the past 2 years.
Based on SEC 10-K filings.
-$44M in FY2019.
Improved from -$60M to -$44M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, free cash flow increased 16.7% year-over-year.
- Peak free cash flow was recorded in FY2014.
- Lowest free cash flow in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | -$43.8M | +16.7% |
| FY2018 | -$52.6M | +12.5% |
| FY2017 | -$60.1M | -112.5% |
| FY2016 | -$28.3M | -88.4% |
| FY2015 | -$15.0M | -10.5% |
| FY2014 | -$13.6M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026